vs

Side-by-side financial comparison of AMERICAN REALTY INVESTORS INC (ARL) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

AMERICAN REALTY INVESTORS INC is the larger business by last-quarter revenue ($13.0M vs $12.5M, roughly 1.0× Avidity Biosciences, Inc.). AMERICAN REALTY INVESTORS INC runs the higher net margin — 75.2% vs -1398.3%, a 1473.5% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 8.1%). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 4.6%).

Weingarten Realty Investors was a real estate investment trust that invested in shopping centers, primarily in the Southern United States and primarily with grocery stores as the anchor stores. In August 2021, the company was acquired by Kimco Realty.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

ARL vs RNA — Head-to-Head

Bigger by revenue
ARL
ARL
1.0× larger
ARL
$13.0M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+426.0% gap
RNA
434.0%
8.1%
ARL
Higher net margin
ARL
ARL
1473.5% more per $
ARL
75.2%
-1398.3%
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
4.6%
ARL

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
ARL
ARL
RNA
RNA
Revenue
$13.0M
$12.5M
Net Profit
$9.8M
$-174.4M
Gross Margin
Operating Margin
-23.3%
-1513.5%
Net Margin
75.2%
-1398.3%
Revenue YoY
8.1%
434.0%
Net Profit YoY
6175.8%
-117.0%
EPS (diluted)
$0.60
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARL
ARL
RNA
RNA
Q4 25
$13.0M
Q3 25
$12.8M
$12.5M
Q2 25
$12.2M
$3.8M
Q1 25
$12.0M
$1.6M
Q4 24
$12.0M
$3.0M
Q3 24
$11.6M
$2.3M
Q2 24
$11.8M
$2.0M
Q1 24
$11.9M
$3.5M
Net Profit
ARL
ARL
RNA
RNA
Q4 25
$9.8M
Q3 25
$129.0K
$-174.4M
Q2 25
$2.8M
$-157.3M
Q1 25
$3.0M
$-115.8M
Q4 24
$-161.0K
$-102.3M
Q3 24
$-17.5M
$-80.4M
Q2 24
$1.2M
$-70.8M
Q1 24
$1.8M
$-68.9M
Operating Margin
ARL
ARL
RNA
RNA
Q4 25
-23.3%
Q3 25
-12.3%
-1513.5%
Q2 25
-8.3%
-4448.7%
Q1 25
-6.8%
-8360.9%
Q4 24
-14.8%
-4069.6%
Q3 24
-17.8%
-4200.9%
Q2 24
-10.8%
-4040.4%
Q1 24
-12.7%
-2178.6%
Net Margin
ARL
ARL
RNA
RNA
Q4 25
75.2%
Q3 25
1.0%
-1398.3%
Q2 25
23.2%
-4089.3%
Q1 25
24.7%
-7360.0%
Q4 24
-1.3%
-3439.5%
Q3 24
-150.4%
-3441.7%
Q2 24
9.9%
-3461.8%
Q1 24
14.7%
-1943.4%
EPS (diluted)
ARL
ARL
RNA
RNA
Q4 25
$0.60
Q3 25
$0.01
$-1.27
Q2 25
$0.18
$-1.21
Q1 25
$0.18
$-0.90
Q4 24
$-0.01
$-0.80
Q3 24
$-1.08
$-0.65
Q2 24
$0.07
$-0.65
Q1 24
$0.11
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARL
ARL
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$89.1M
$350.2M
Total DebtLower is stronger
$214.4M
Stockholders' EquityBook value
$617.4M
$1.9B
Total Assets
$1.1B
$2.1B
Debt / EquityLower = less leverage
0.35×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARL
ARL
RNA
RNA
Q4 25
$89.1M
Q3 25
$82.8M
$350.2M
Q2 25
$73.5M
$243.9M
Q1 25
$88.7M
$254.2M
Q4 24
$99.7M
$219.9M
Q3 24
$131.6M
$370.2M
Q2 24
$127.5M
$575.8M
Q1 24
$130.9M
$471.4M
Total Debt
ARL
ARL
RNA
RNA
Q4 25
$214.4M
Q3 25
$227.0M
Q2 25
$216.0M
Q1 25
$201.7M
Q4 24
$185.4M
Q3 24
$183.8M
Q2 24
$181.0M
Q1 24
$181.8M
Stockholders' Equity
ARL
ARL
RNA
RNA
Q4 25
$617.4M
Q3 25
$607.8M
$1.9B
Q2 25
$607.8M
$1.2B
Q1 25
$604.9M
$1.3B
Q4 24
$601.8M
$1.4B
Q3 24
$602.2M
$1.5B
Q2 24
$619.9M
$1.2B
Q1 24
$618.8M
$830.9M
Total Assets
ARL
ARL
RNA
RNA
Q4 25
$1.1B
Q3 25
$1.1B
$2.1B
Q2 25
$1.1B
$1.4B
Q1 25
$1.0B
$1.5B
Q4 24
$1.0B
$1.6B
Q3 24
$1.0B
$1.6B
Q2 24
$1.0B
$1.3B
Q1 24
$1.0B
$951.5M
Debt / Equity
ARL
ARL
RNA
RNA
Q4 25
0.35×
Q3 25
0.37×
Q2 25
0.36×
Q1 25
0.33×
Q4 24
0.31×
Q3 24
0.31×
Q2 24
0.29×
Q1 24
0.29×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARL
ARL
RNA
RNA
Operating Cash FlowLast quarter
$-5.6M
$-156.2M
Free Cash FlowOCF − Capex
$-156.9M
FCF MarginFCF / Revenue
-1257.6%
Capex IntensityCapex / Revenue
5.7%
Cash ConversionOCF / Net Profit
-0.57×
TTM Free Cash FlowTrailing 4 quarters
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARL
ARL
RNA
RNA
Q4 25
$-5.6M
Q3 25
$8.0M
$-156.2M
Q2 25
$-2.9M
$-199.7M
Q1 25
$-7.4M
$-124.8M
Q4 24
$1.1M
$-99.9M
Q3 24
$13.5M
$-65.6M
Q2 24
$-503.0K
$-65.0M
Q1 24
$3.9M
$-70.4M
Free Cash Flow
ARL
ARL
RNA
RNA
Q4 25
Q3 25
$-156.9M
Q2 25
$-203.0M
Q1 25
$-128.6M
Q4 24
$-103.8M
Q3 24
$-67.3M
Q2 24
$-65.5M
Q1 24
$-71.3M
FCF Margin
ARL
ARL
RNA
RNA
Q4 25
Q3 25
-1257.6%
Q2 25
-5277.1%
Q1 25
-8174.3%
Q4 24
-3491.0%
Q3 24
-2881.8%
Q2 24
-3204.6%
Q1 24
-2012.3%
Capex Intensity
ARL
ARL
RNA
RNA
Q4 25
Q3 25
5.7%
Q2 25
86.9%
Q1 25
238.6%
Q4 24
131.7%
Q3 24
72.9%
Q2 24
26.0%
Q1 24
25.8%
Cash Conversion
ARL
ARL
RNA
RNA
Q4 25
-0.57×
Q3 25
61.81×
Q2 25
-1.03×
Q1 25
-2.50×
Q4 24
Q3 24
Q2 24
-0.43×
Q1 24
2.21×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons